Objective: The aim of this study to evaluate the anti bacterial and anti-inflammatory effectiveness of Boswellia serrata standardized extract by in-vitro methods. Methods: The agar diffusion method has been adopted to evaluate the in vitro antibacterial activity of Boswellia serrata against Staphylococcus aureus and Escherchia coli by using Ciprofloxacin as standard drug. The test substance has been screened at different concentrations such as 25, 50, 100, 250, 500 and 1000 µg/ml. The in vitro anti inflammatory activities of Boswellia serrata standardized extract was performed at three different concentrations such as 10µg, 50µg and 100µg by using hyaluronidase enzyme inhibition assay. The absorbance of the final reaction mixture was measured at 600 nm. Results: The in vitro antibacterial activity of the test sample was evaluated at different concentrations and the diameter of inhibition zones in mm was evaluated. The results revealed that, Boswellia serrata extract at different concentrations provides a promising antimicrobial activity against S. aureus and E.coli. The test compound was screened in a range of 100µg -1000µg in the reaction mixture. The hyaluronidase inhibition potential of test compound was evaluated and calculated as the percentage ratio of the absorbance in presence of the test compound vs. positive control. Standard drug Indomethacin (Indo) was used as reference standard. The result revealed that the maximum (84.847%) hyaluronidase inhibition was observed at 100µl where as standard drug Indomethacin showed (98.21%) inhibition. Conclusions: The Standardized extract of Boswellia serrata exhibit significant anti bacterial and hyaluronidase inhibition activity in a dose dependent manner.
Cite this article:
Suruj Kaushik, Amit Roy, Prerna Purabiya, Trilochan Satapathy. Anti Bacterial and In Vitro Anti-inflammatory Potential of Boswellia seratta: A Potent Bioactive Compound. Research J. Pharm. and Tech 2020; 13(3): 1079-1082. doi: 10.5958/0974-360X.2020.00198.5
Suruj Kaushik, Amit Roy, Prerna Purabiya, Trilochan Satapathy. Anti Bacterial and In Vitro Anti-inflammatory Potential of Boswellia seratta: A Potent Bioactive Compound. Research J. Pharm. and Tech 2020; 13(3): 1079-1082. doi: 10.5958/0974-360X.2020.00198.5 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-3-3
1. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J et.
al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget.
2. David D. Chaplin. Overview of the Immune Response.
J Allergy Clin Immunol. 2010; 125(2 - 2):3–23.
3. Suresh E. Diagnosis of early rheumatoid arthritis:
what the non-specialist needs to know. J R Soc Med. 2004; 97(9): 421–424.
4. Pereira J, Anoop S, and Pettah GJ. A Case of Chronic
Inflammation of the Ankle Joint with Subtle Signs of Inflammation: A Rare Presentation
of Tuberculosis Ankle. J Orthop Case Rep. 2017; 7(1):87–90.
5. Smith SW, Chalupa P and Hasan MS. Infectious arthritis:
clinical features, laboratory findings and treatment. Clin Microbiol Infect. 2006;12:
6. Rasigade JP, Vandenesch F. Staphylococcus aureus:
a pathogen with still unresolved issues. Infect. Genet. Evol. 2014;2 :510-14.
7. Chambers HF. Community-associated MRSA--resistance
and virulence converge. N. Engl. J. Med. 2005; 352(14):1485-87.
8. Boucher HW, Corey GR. Epidemiology of methicillin-resistant
Staphylococcus aureus. Clin. Infect. Dis. 2008; 46(5):344-49.
9. Rasmussen RV, Fowler VG, Skov R, Bruun NE. Future
challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA".
Future Microbiology. 2011; 6 (1): 43–56.
10. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler
VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations,
and management". Clinical Microbiology Reviews. 2015; 28 (3): 603–61.
11. Nataro and Kaper JB. Diarrheagenic Escherichia coli.
Clin Microbiol Rev. 1998; 11(1): 142–201.
12. Shukla PK, Bhatnagar P, Yadav R. Boswellia serrata:
a gum-oleoresin yielding tree. Vaniki Sandesh. 2005; 29:23–26.
13. Upaganlawar A, Ghule B. Pharmacological activities
of Boswellia serrata Roxb. – Mini review. Ethnobot Leaflets. 2009; 13: 766–74.
14. Atal CK, Singh B, Kour S, Singh S, Singh GB, Gupta
CL. Primate chronic toxicity study on salai guggal ex-Boswellia serrata – a new
anti asthmatic drug. Indian J Pharmacol. 1983; 15:35.
15. Singh GB, Bani S, Singh S. Toxicity and safety evaluation
of Boswellic acids. Phytomedicine. 1996; 3:87–90.
16. Threlfall EJ., fisher IST, ward L, Tschape H. &
Gernersmidt P. Harmonization of antibiotic susceptibility testing for Salmonella:
Results of a study by 18 national reference laboratories within the European Union-funded
Enter-Net group. Microb. Drug Resist. 1999; 5: 195–199.
17. Walker RD. Antimicrobial susceptibility testing
and interpretation of results. In: Antimicrobial Therapy in Veterinary Medicine,
Prescott J.F., Baggot J.D., Walker R.D., eds. Ames, IA, Iowa State University Press,
18. Ling SK., Tanaka T, and Kouno I. Effects of iridoids
on lipoxygenase and hyaluronidase activities and their activation by β - glucosidase
in the presence of amino acids. Biol. Pharm. Bull. 2003; 26(3): 352— 356.